About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDPhase 3NCT00394901

A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

The purpose of this study is to evaluate efficacy and safety of pregabalin in the treatment of postherpetic neuralgia in a dose-ranging manner.

Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.•39 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Visual Analogue Scale (VAS) of pain is higher than 40 mm.
•Pain is sustained for more than 3 months after healing of herpes zoster skin rash.

Exclusion Criteria

•Malignancy within the past 2 years.
•Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.
•Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).
•Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.
•Skin conditions in the affected dermatome that could alter sensation.

Related studies

TERMINATEDPhase 2

A Research Study to Evaluate the Safety and Effectiveness of MK0686 for the Treatment of Postherpetic Neuralgia (Also Known as PHN or Post Shingles Pain) (0686-005)

NCT00282763 · Neuralgia, Postherpetic

TERMINATEDPhase 2

Safety and Preliminary Efficacy of MK0759 in Postherpetic Neuralgia (PHN)(0759-004)

NCT00245544 · Neuralgia, Postherpetic

COMPLETEDPhase 1

Neuropathic Pain Syndrome Patient Study (MK-0000-072)

NCT00570310 · Neuralgia, Postherpetic, Diabetic Neuropathy, and more

COMPLETEDPhase 2

A 16 Week Study Evaluating Levetiracetam in the Treatment of Post Herpetic Neuralgia (PHN)

NCT00160511 · Neuralgia, Postherpetic

COMPLETEDPhase 2

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

NCT01129531 · Neuralgia, Postherpetic

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 9, 2021Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE3

Enrollment372

Start dateSep 2006

Last updatedFeb 9, 2021

Condition

Neuralgia, Postherpetic

Locations shown

Pfizer Investigational Site

Nagoya, Aichi-ken

Pfizer Investigational Site

Ichikawa, Chiba

Pfizer Investigational Site

Urayasu, Chiba

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 9, 2021Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions